Diagnostyka S.A. (WSE:DIA)

Poland · Delayed Price · Currency is PLN

161.60

+4.10 (2.60%)

At close: May 6, 2026

-1.46% (1Y)

Market Cap	5.46B +14.1%
Revenue (ttm)	2.42B +23.6%
Net Income	251.60M +12.7%
EPS	7.45 +12.6%
Shares Out	33.76M
PE Ratio	21.69
Forward PE	17.00
Dividend	3.31 (2.10%)
Ex-Dividend Date	Jun 1, 2026

Volume	109,744
Average Volume	104,457
Open	160.00
Previous Close	157.50
Day's Range	158.10 - 162.60
52-Week Range	146.40 - 219.90
Beta	n/a
RSI	48.78
Earnings Date	Apr 20, 2026

About Diagnostyka

Diagnostyka S.A. operates as a medical laboratory. The company was founded in 1998 and is headquartered in Kraków, Poland.

Industry Diagnostics & Research

Sector Healthcare

Founded 1998

Employees 7,836

Stock Exchange Warsaw Stock Exchange

Ticker Symbol DIA

Financial Performance

In 2025, Diagnostyka's revenue was 2.41 billion, an increase of 23.60% compared to the previous year's 1.95 billion. Earnings were 251.60 million, an increase of 12.66%.

Financial Statements

News

Diagnostyka Earnings Call Transcript: Q4 2025

Revenue grew 23.6% year-over-year, driven by strong B2B and public health program growth, with EBITDA up 15% and net profit up nearly 13%. Regulatory changes in DI and SAP implementation pose short-term challenges, but stable margins and robust cash flow support continued investment and dividends.

15 days ago - Transcripts

Diagnostyka Earnings Call Transcript: Q3 2025

Q3 2025 saw revenue up 26% year-on-year and recurring EBITDA over PLN 150 million, driven by higher test volumes, price increases, and diagnostic imaging. Strong cash flow and robust financials support ongoing acquisitions and innovation, with stable outlook and dividend policy.

5 months ago - Transcripts

Diagnostyka Earnings Call Transcript: Q2 2025

Test volumes and profits rose year-over-year, with revenue up 22.5% and EBITDA up 24%. Strong cash flow and disciplined capital allocation support ongoing M&A and dividend policy, while wage increases and seasonality may pressure margins in H2.

8 months ago - Transcripts

Diagnostyka Earnings Call Transcript: Q1 2025

Q1 2025 saw strong revenue and EBITDA growth, driven by higher test volumes, price increases, and diagnostic imaging expansion. Cash flow and balance sheet remain robust, with stable margins and a positive outlook for continued growth and M&A activity.

1 year ago - Transcripts